학술논문

The transcriptional programme of the androgen receptor ( AR) in prostate cancer.
Document Type
Article
Source
BJU International. Mar2014, Vol. 113 Issue 3, p358-366. 9p.
Subject
*ANDROGEN receptors
*PROSTATE cancer treatment
*CELL cycle
*ABIRATERONE acetate
*GENETIC transcription
*STAT proteins
Language
ISSN
1464-4096
Abstract
The androgen receptor ( AR) is essential for normal prostate and prostate cancer cell growth., AR transcriptional activity is almost always maintained even in hormone relapsed prostate cancer (HRPC) in the absence of normal levels of circulating testosterone., Current molecular techniques, such as chromatin-immunoprecipitation sequencing (ChIP-seq), have permitted identification of direct AR-binding sites in cell lines and human tissue with a distinct coordinate network evident in HRPC., The effectiveness of novel agents, such as abiraterone acetate (suppresses adrenal androgens) or enzalutamide ( MDV3100, potent AR antagonist), in treating advanced prostate cancer underlines the on-going critical role of the AR throughout all stages of the disease., Persistent AR activity in advanced disease regulates cell cycle activity, steroid biosynthesis and anabolic metabolism in conjunction with regulatory co-factors, such as the E2F family, c- Myc and signal transducer and activator of transcription ( STAT) transcription factors. Further treatment approaches must target these other factors. [ABSTRACT FROM AUTHOR]